Is Tyra Biosciences, Inc. (TYRA) a Buy, Sell, or Hold?
Tyra Biosciences, Inc.
NASDAQ:TYRA
$31.83 USD
-$1.05 (-3.19%)
- Volume
- 210.07K
- Average Volume
- 947.4K
- Market Capitalization
- $1.89B
- P/E Ratio
- -14.60
- Dividend Yield
- 0.00%
- Price Target
- $51.50
- Year High
- $40.65
- Year Low
- $9.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $20.49
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Todd Harris |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TYRA |
| CUSIP | 90240B106 |
| CIK | 0001863127 |
| Web | https://www.tyra.bio |
| Phone | 619 728 4760 |
| Currency | USD |
| Employees | 87 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 20.49 |
| Quick Ratio | 20.49 |
| Cash Ratio | 4.41 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.66 |
| Price / Cash Flow | -18.47 |
| Price / Book | 5.07 |
Price Target and Rating
| Average Stock Price Forecast | $51.50 |
| High Stock Price Forecast | $59.00 |
| Low Stock Price Forecast | $42.00 |
| Forecast Upside/Downside | -38.19% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.01 |
| Trailing P/E Ratio | -14.60 |
| PEG Ratio | 0.54 |
| P/E Growth | 0.54 |
| Net Income | $-119.95M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -42.66% |
| Return on Assets | -31.82% |
Financials Score
| AltmanZ Score | 46.60 |
| Piotroski Score | 1.00 |
| Working Capital | 375.36M |
| Total Assets | 412.04M |
| Ebit | -131.1M |
| Market Cap | 1.96B |
| Total Liabilities | 24.46M |
Poll Results
About Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founde ... d in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
2026-05-21 08:00:00
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares
2026-05-17 14:41:48
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
2026-05-13 17:20:44
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
2026-05-13 08:00:00
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - - Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 - CARLSBAD, Calif., May 13, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress.
Tyra Biosciences to Participate in Upcoming Investor Conferences
2026-05-07 16:05:00
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NV TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Format: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLocation: Virtual Jefferies Global Healthcare Conference Format: Hybrid fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ETLocation: New York, NY A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of “Moderate Buy” by Analysts
2026-04-27 02:22:54
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
2026-04-17 08:00:00
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.
Frequently Asked Questions
-
What is the current Tyra Biosciences, Inc. (TYRA) stock price?
-
Tyra Biosciences, Inc.(NASDAQ:TYRA) stock price is $31.83 in the last trading session. During the trading session, TYRA stock reached the peak price of $40.65 while $9.96 was the lowest point it dropped to. The percentage change in TYRA stock occurred in the recent session was --3.19% while the dollar amount for the price change in TYRA stock was -$-1.05.
-
TYRA's industry and sector of operation?
-
The NASDAQ listed TYRA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TYRA?
-
Julia Rueb | VP of Finance & Principal Accounting Officer
Bhavesh Ashar | Chief Operating Officer
Daniel Bensen | Co-Founder & Chief Discovery Officer
Sarah Honig | Senior Vice President of Corporate Development & Strategy
Robert L. Hudkins | Chief Technology Officer -
How many employees does TYRA have?
-
Number of TYRA employees currently stands at 87. TYRA operates from 2656 State Street, Carlsbad, CA 92008, US.
-
Link for TYRA official website?
-
Official Website of TYRA is: https://www.tyra.bio
-
How do I contact TYRA?
-
TYRA could be contacted at phone #619 728 4760 and can also be accessed through its website. TYRA operates from 2656 State Street, Carlsbad, CA 92008, US.
-
How many shares of TYRA are traded daily?
-
The average number of TYRA shares traded daily for last 3 months was 947.4K.
-
What is the market cap of TYRA currently?
-
The market value of TYRA currently stands at $1.89B with its latest stock price at $31.83